Fat Grafting in Milan Italy
As we grow older our face become more and more affected by the sun, gravity and use of expression muscles (chewing, smiling, etc). Deep tissues loose the ability to maintain a young look and expression marks appear on our faces. Fat grafting can help you fill the defects and regain younger appearance. It can be used to fill expression folds, sunken checks, scars and lips. This procedure is not sufficient to treat deep defects like multiple grooves around the mouse of heavy smokers. It can be done as isolated treatment or as a combination with laser, facelift and botox.
During the procedure the surgeon performs a liposuction from various body parts like thighs, tummy and buttocks and then injects the fat into selected areas needs to be filled. After disinfection of the donor and recipient areas, they are being sedated using local anesthetics. Sedative drugs also can be used, if so you may need an escort to avoid driving under their influence. For liposuction the surgeon uses wide needle or canola. After a short treatment the fat is injected to the desired site. The recipient area is usually bandaged. In order to fill sunken chicks often over filling is required because of absorption process of some of the fat injected. This can make your face appear over swollen immediately after the operation.
If the area treated is extensive it is advisable to restrain from activities after the treatment. Although most of the patients can go back to their daily activities right away. There might be redness, swelling and small hemorrhages around both the donor and the recipient sites. The severity of those symptoms usually depends on the magnitude of the procedure. It is advisable to avoid sun exposure until the above disappear (after approximately 48 hours). There is no limitation to use make-up. The swelling can last for weeks especially if the area is large. Every operation has its ricks. The fat being taken from the patient's body doesn't cause allergic responses. There is a small chance of infection.
You must remember that the effect of the injection is only temporary. Due to their biological nature the injected materials disassemble by the body. The duration of the effect depends on genetics, age, skin quality, life style and the area being filled. There are selected cases where the results lasted for a year, but in most cases half of the effect disappears after 3-6 month.
More Milan info...
Milan Museums
Milan offers the visitor a large variety of art museums, mainly of Italian Renaissance and Baroque.
Cenacolo Vinciano [18] Leonardo da Vinci's famous "Last Supper". Tickets should be reserved at least a few days before the visit. Cancelled reservations are sold from 8:15 every morning (if there are any).
Pinacoteca di Brera [19], on Brera Street. Reach by subway MM2 Lanza Station, MM3 Montenapoleone Station, tram lines 1, 4, 8, 12, 14, 27 or buses 61 and 97.
Pinacoteca Ambrosiana [20] -
Milan Restaurants
At the two Osteria del Gnocco Fritto the 4.5 euro cover charge includes baskets of fried, square, hollow, hand-size pastries (similar to sopapillas) accompanied by meats, cheeses, or jams (8 to 11 euro). At Via Pestalozzi, 16 (tel. 02 8912.2631) and off the Grand Canal at Via Pasquale Paoli, 2 (tel. 02 5810.0216).
The Osteria dei Formaggi on the Grand Canal (Alzaia Naviglio Grande, 54) serves all manner of excellent cheese dishes in an intimate dining room heavily decorated with cows. (tel. 02 8940.9415)
-
Plastic Surgery News...
- The National Institute for Health and Clinical Excellence (NICE) has published an appraisal consultation document (ACD – draft guidance) on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. The guidance recommends (direct from source):
1.1 Alendronate is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who have a T-score of -2.5 SD or below. In women aged 75 years or older, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible.
When the decision has been made to initiate treatment with alendronate, the preparation prescribed should be chosen on the basis of the lowest acquisition cost available.
1.2 Risedronate and etidronate are recommended as alternative treatment options for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
• who are unable to comply with the special instructions for the administration of alendronate, have a contraindication to, or are intolerant of alendronate (as defined in section 1.7) and
• who also have a T-score, age and number of independent clinical risk factors for fracture (see section 1.5) - please refer to table in the ACD for T-scores (SD) at (or below) which risedronate or etidronate is recommended.
1.3 Raloxifene and strontium ranelate are recommended as alternative treatment options for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
• who are unable to comply with the special instructions for the administration of alendronate and risedronate, or who have a contraindication to or are intolerant of alendronate and risedronate (as defined in section 1.6) and
• who also have a T-score, age and number of independent clinical risk factors for fracture (see section 1.5) - please refer to table in the ACD for T-scores (SD) at (or below) which raloxifene or strontium ranelate is recommended.
1.4 Teriparatide is recommended as an alternative treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
• who are unable to take alendronate and risedronate, have a contraindication to, or are intolerant of alendronate and risedronate (as defined in section 1.6) or who have a contraindication to, or are intolerant of strontium ranelate (as defined in section 1.7) and
• who are 65 years or older and have an extremely low BMD (with a T-score of -4 SD or below), or a very low BMD (with a T-score of -3.5 SD or below) plus multiple fractures (that is, more than two), or who are aged 55-64 years and have a T-score of -4 SD or below plus multiple fractures (that is, more than two).
1.5 For the purposes of this guidance, independent clinical risk factors for fracture to be considered are: parental history of hip fracture, alcohol intake of 4 or more units per day, and severe, long-term rheumatoid arthritis.
1.6 For the purposes of this guidance, intolerance of alendronate and risedronate is defined as persistent upper gastrointestinal disturbance that is sufficiently severe to warrant discontinuation of treatment and that occurs even though the instructions for administration have been followed correctly.
1.7 For the purpose of this guidance, intolerance of strontium ranelate is defined as persistent nausea or diarrhoea, either of which warrants discontinuation of treatment.
1.8 Women who are currently receiving treatment with one of the drugs covered by this guidance, but for whom therapy would have not been recommended according to sections 1.1 to 1.4, should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
The key dates for this appraisal are:
Closing date for comments: 23 April 2008
Second Appraisal Committee meeting: 01 May 2008
- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, disclosed that it has filed a provisional patent submission entitled, "Method and Apparatus for Increasing Contaminant Clearance Rates during Extracorporeal Fluid Treatment," with the U.S. Patent and Trademark Office (USPTO).